Paul K. Laikind is CEO at METABASIS THERAPEUTICS INC (MBRX). They have made 1 open-market trade across 1 company since 2008, most recently 2008-11-19.
CIK 0001292402
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $4K since 2008, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MBRX | 702,620 | $197K |
Shares reported on the most recent Form 4, priced at the 2008-11-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MBRX | BUY | 2008-11-18 | 2008-11-19 | $0.64 | $4K | -29.0% | -11.0% | -11.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.